EP Patent

EP4681704A1 — New formulations of pitolisant

Assigned to Bioprojet Pharma SAS · Expires 2026-01-21 · 0y expired

What this patent protects

The present disclosure relates to new formulations comprising an alkalinizing agent for improving absorption of active pharmaceutical ingredients, such as pitolisant.

USPTO Abstract

The present disclosure relates to new formulations comprising an alkalinizing agent for improving absorption of active pharmaceutical ingredients, such as pitolisant.

Drugs covered by this patent

pitolisant-hydrochloride (PITOLISANT HYDROCHLORIDE)

Patent Metadata

Patent number: EP4681704A1
Jurisdiction: EP
Classification: —
Expires: 2026-01-21
Drug substance claim: No
Drug product claim: No
Assignee: Bioprojet Pharma SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.